1 / 16

Disclosures

Treatment with the second-generation HCV protease inhibitor BI 201335 results in high and consistent SVR rates: Results from SILEN-C1 in HCV genotype-1 treatment-naïve patients across different baseline factors. Disclosures. Introduction. SILEN-C1 trial. Virologic response a. Methods.

bozica
Download Presentation

Disclosures

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Treatment with the second-generation HCV protease inhibitor BI 201335 results in high and consistent SVR rates:Results from SILEN-C1 in HCV genotype-1 treatment-naïve patients across different baseline factors

  2. Disclosures

  3. Introduction

  4. SILEN-C1 trial

  5. Virologic responsea

  6. Methods

  7. Baseline characteristics

  8. Virologic response by age and gender

  9. Virologic response by baseline ALT and GGT

  10. Virologic response by baseline HCV RNA

  11. Virologic response by HCV GT-1 subtype

  12. Virologic response by IL28B

  13. Baseline predictors of SVR

  14. Baseline predictors of SVR

  15. Discussion

  16. Acknowledgements

More Related